Cytodyn Inc (CYDY)

[Leronlimab4DaWin]

This is pretty simple math:

Here a very large sample size was taken (10k) for hospitalized patients (same as CD12 trial)

https://clinicaltrials.gov/ct2/show/NCT04381936

The results were 18% mortality rate

https://www.recoverytrial.net/news/statement-from-the-recovery-trial-chief-investigators-15-january-2021-recovery-trial-closes-recruitment-to-convalescent-plasma-treatment-for-patients-hospitalised-with-covid-19

In order for Leronlimab to achieve a p-value <0.05, on 90 deaths, they need placebo mortality rate to be over 31%. Even emerginggrowth website agrees with analysis

https://emerginggrowth.com/cytodyn-update-reveals-q1-sales-pipeline-philippine-eua-nasdaq-uplisting-high-likelihood-of-approval/


It seems improbably for that to be the case given Leronlimab excludes the sickest from its trial (look in exclusions)
https://clinicaltrials.gov/ct2/show/NCT04347239?cond=leronlimab&draw=2&rank=6

Anything is possible but this seems highly improbable.